OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting Epstein-Barr Virus.
